Impact of the expression of cyclin-dependent kinase inhibitor p27(Kip1) and apoptosis in tumor cells on the overall survival of patients with non- early stage gastric carcinoma

Cancer

Volumn 85, Issue 8, 1999, Pages 1711-1718

  Ohtani, Masahiro ^a   Isozaki, Hiroshi ^a   Fujii, Keizo ^a   Nomura, Eiji ^a   Niki, Masami ^a   Mabuchi, Hideaki ^a   Nishiguchi, Kanji ^a   Toyoda, Masao ^a   Ishibashi, Takashi ^a   Tanigawa, Nobuhiko ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Apoptosis; Gastric carcinoma; P27(Kip1) expression; Prognosis

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR;

APOPTOSIS; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA; TISSUE SECTION;

ADENOCARCINOMA; AGED; APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE PROGRESSION; FEMALE; GASTRECTOMY; HUMANS; LIFE TABLES; LYMPHATIC METASTASIS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 0033561154     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990415)85:8<1711::AID-CNCR10>3.0.CO;2-L     Document Type: Article

References (46)

1. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994; 79:515-55.
2. Hunter T, Pines J. Cyclins and cancer K: cyclin D and CDK inhibitors come of age. Cell 1994;79:573-82.
3. MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and CDK inhibitors: implication in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995;5:127-56.
4. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts J, Tempst P, et al. Cloning of p27, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
5. Toyoshima T, Hunter T. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 1994;78: 67-74.
6. Kip1 accumulation during the cell cycle. Science 1996;271:1861-4.
7. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995;55:2910-9.
8. Harper JW, Adami GR, Wei N, Kayamarsl K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
9. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4.
10. Serrano M, Hannon GJ, Beach DA. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin/cdk4. Nature 1993;366:704-7.
11. Katayose Y, Kim M, Amol NS, Rakkar ZL, Kenneth H, Prem S. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997;57: 5441-5.
12. Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene 1997;15:2991-7.
13. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, et al. p27, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 1994;8:9-22.
14. Pagano M, Romero-Beer P, Glass S, Tam SW, Theodoras A, Rolfe M, et al. Targeting ubiquitin-mediated degradation for proliferation inhibitors. Cancer genes. New York: Plenum, 1997;255-68.
15. Pagano M, Tam SW, Theodoras AM, Romero-Beer P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
16. Spataro V, Norbury C, Harris AL. The ubiquitin-proteasome pathway in cancer. Br J Cancer 1998;77:448-55.
17. Kip1 and cyclin E, alone and in combination, correlates with survival in young breast cancer patients. Nat Med 1997;3:222-5.
18. Catzavelos C, Bhattacharya N, Ung YC, Willson JA, Roncari L, Sandhu C, et al. Decreased level of the cell-cycle inhibitor p27 protein: prognostic implication in primary breast cancer. Nat Med 1997;3:227-30.
19. Tan P, Cady B, Wanner M, Worland P, Cukor B, Galluzzi CM, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 1997;57:1259-63.
20. Yasui W, Kudo Y, Semba S, Yokozaki H, Tahara E. Reduced expression of cyclin-dependent kinase inhibitor p27 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res 1997;88:625-9.
21. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, et al. p27 expression and gastric carcinoma. Nat Med 1997;3:593.
22. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta G, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:152-4.
23. Esposito V, Baldi A, Luca AD, Groger AM, Loda M, Giacomo G, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57:3381-5.
24. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998;58: 542-8.
25. Atul B, Pankaj JP, Adil JA, James PB, Gauri CB, Francis MG, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995;55:1811-6.
26. Lipponen P, Aaltomaa S, Kosma VM, Syrjanen K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 1994;30A:2068-73.
27. Mark JA, Angus HM, Andrew HW. Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras, and HPV oncogenes. Am J Pathol 1994;144:1045-57.
28. Soini Y, Virkajarvi N, Lehto VP, Paakko P. Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival. Br J Cancer 1996;73:1025-30.
29. Lu C, Tanigawa N. Spontaneous apoptosis is inversely related to intratumoral microvessel density in gastric carcinoma. Cancer Res 1997;57:221-4.
30. Japanese Research Society for Gastric Cancer. The general rules for gastric cancer. Jpn J Surg 1993;12:1-89.
31. Katai H, Maruyama K, Okajima K. Mode of recurrence after gastric cancer surgery. Dig Surg 1994;11:99-103.
32. Moriguchi M, Maehara Y, Korenaga D, Sugimachi K, Hayashi Y, Nose Y. Prediction of survival time after curative surgery for advanced gastric cancer. Eur J Surg Oncol 1992; 18:287-92.
33. Sano T, Sasako M, Kinoshita T, Maruyama K. Recurrence of early gastric cancer: follow-up of 1475 patients and review of the Japanese literature. Cancer 1993;72:3174-8.
34. Ichikura T, Fujino K, Ikawa H, Tomimatsu S, Uefuji K, Tamakuma S. Proposal of a risk score for recurrence in patients with curatively resected gastric cancer. Surg Today 1993;23:759-64.
35. Maruyama K. The most important prognostic factors for gastric cancer patients: a study using univariate and multivariate analyses. Scand J Gastroenterol 1987;22:63-8.
36. Roder JD, Bottcher K, Siewert JR, Busch R, Hermanek P, Meyer HJ. Prognostic factors in gastric carcinoma: results of German Gastric Carcinoma Study 1992. Cancer 1993; 72:2089-97.
37. Soos TJ, Kiyokawa H, Yan JS, Rubin MS, Giordano A, DeBlasio A, et al. Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ 1996;7:135-46.
38. Gerdes J, Schwab U, Lemke H, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133:1710-5.
39. Paggi MG, Baldi A, Bonetto F, Giordano A. Retinoblastoma protein family in cell cycle and cancer a review. J Cell Biochem 1996;62:418-30.
40. Lee MH, Reynisdottir I, Massague J. Cloning of p57, a cyclin-dependent kinase inhibitor with a unique domain structure and tissue distribution. Genes Dev 1995;9:639-49.
41. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, et al. p57, a structurally distinct member of the p21 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995;9:650-2.
42. White E. Life, death, and the pursuit of apoptosis. Genes Dev 1996;10:1-15.
43. Gorospe M, Wang X, Guyton KZ, Holbrook NJ. Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2. Mol Cell Biol 1996;16:6654-60.
44. Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, Korsmeyer SJ. p21 (Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene 1997; 14:929-36.
45. Yang ZY, Perkins ND, Ohno T, Nabel EG, Nabel GJ. The p21 cyclin-dependent kinase inhibitor suppresses tumorgenicity in vivo. Nat Med 1995;1:1052-6.
46. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.